<img height="1" width="1" src="https://www.facebook.com/tr?id=841180246705289&amp;ev=PageView &amp;noscript=1">

We measure our impact by patient outcomes and the success of our partners. Learn More 

FDA issues rare emergency authorization for an algorithm used to inform Covid-19 care

October 8, 2020

In less than a year, the pandemic has spurred the development of countless artificial intelligence models designed to aid in the diagnosis of Covid-19 and spot early warning signs of severe illness among those infected. But so far, only a few have received emergency use authorization from the Food and Drug Administration. That scarcity is a sign of the newness of these tools — as well as the murkiness of the regulatory landscape at a time when unapproved algorithms are being widely tested and rolled out in the clinic.

The latest such authorization, which amounts to a conditional approval of a product, was granted to a system meant to predict whether hospitalized Covid-19 patients are at risk of needing intubation — a heads-up that could allow clinicians to take mitigating steps and plan accordingly. The model was developed by Dascena, a San Francisco Bay Area company working on clinical machine learning systems for conditions including sepsis and acute kidney injury.

Read more here.

Interested in learning more?

Proud sponsor of Sepsis Alliance